Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
NCT03519958 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2018-11-16
Summary
To describe the T790M mutation status of patients with locally advanced/metastatic NSCLC who progressed on previous EGFR TKI treatment in a real-world setting.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Plasma-tissue testing
EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
James Ho, MBBS · Queen Mary Hospital, Hong Kong
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-30
- Primary Completion
- 2020-11-30
- Completion
- 2020-11-30
More Related Trials
-
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
NCT02988141 ·Status: UNKNOWN
-
EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment
NCT02644889 ·Status: UNKNOWN
-
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
NCT02418234 ·Status: COMPLETED
-
A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples
NCT01382992 ·Status: UNKNOWN
-
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
NCT01775943 ·Status: UNKNOWN
-
Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)
NCT02293733 ·Status: COMPLETED
-
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
NCT04811001 ·Status: UNKNOWN ·Phase: PHASE2
-
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
NCT02575560 ·Status: COMPLETED
-
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC
NCT03916913 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
NCT01776684 ·Status: UNKNOWN ·Phase: NA
-
Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy
NCT03309462 ·Status: COMPLETED ·Phase: NA
-
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
NCT03133234 ·Status: COMPLETED
-
A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)
NCT05737849 ·Status: WITHDRAWN
-
Acquired Resistant Mechanism of the First-generation EGFR TKIs
NCT02804217 ·Status: UNKNOWN
-
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
NCT02886195 ·Status: UNKNOWN ·Phase: PHASE3
-
Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
NCT02353741 ·Status: TERMINATED ·Phase: PHASE2
-
Asia Pacific and Russia Diagnostic Study for EGFR Testing
NCT01788163 ·Status: COMPLETED ·Phase: NA
-
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression
NCT03544814 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA
NCT02811354 ·Status: UNKNOWN ·Phase: PHASE2
-
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
NCT05215548 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
NCT03219970 ·Status: COMPLETED
-
Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
NCT03461185 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
NCT02442349 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
NCT01250119 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I, Study in Chinese NSCLC Patients
NCT02529995 ·Status: COMPLETED ·Phase: PHASE1